Eli Lilly and Company - Ebitda

Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Ebitda" stands at 35.21 Billion United States Dollars for the trailing twelve months (TTM) period ending 06/30/2026, the highest value at least since 12/31/2012, the period currently displayed.

Eli Lilly and Company's second quarter result of 9.25 Billion USD for the item "Ebitda" represents a decrease of -4.58 percent compared to it's first quarter result.

Also, Eli Lilly and Company's second quarter result of 9.25 Billion USD for the item "Ebitda" represents an increase of 23.23 percent compared to it's second quarter result of last year.

Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's second quarter result of 35.21 Billion USD for the item "Ebitda" represents an increase of 5.21 percent compared to it's first quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 79.06 percent compared to the value the year prior.
The 1 year change in percent is 79.06.
The 3 year change in percent is 285.39.
The 5 year change in percent is 301.20.
The 10 year change in percent is 659.66.

The Serie's long term average value is 9.03 Billion United States Dollars. It's latest available value, on 06/30/2026, is 289.85 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 12/31/2017, to it's latest available value, on 06/30/2026, is +782.47%.
The Serie's change in percent from it's maximum value, on 06/30/2026, to it's latest available value, on 06/30/2026, is 0.0%.